Alteplase/microbubble combination therapeutic - ImaRx Therapeutics

Drug Profile

Alteplase/microbubble combination therapeutic - ImaRx Therapeutics

Alternative Names: MRX-801; MRX-801 microbubbles

Latest Information Update: 04 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaRx Therapeutics
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Stroke

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Jun 2009 ImaRX Therapeutics sells MRX 801 to WA 32609 Inc.
  • 04 Jan 2008 Suspended - Phase-I/II for Stroke in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top